Concepedia

Publication | Open Access

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy

DOIFull Paper Access

32

Citations

9

References

2018

Year

Eri Takeshita, Hirofumi Komaki, Yuko Shimizu‐Motohashi, Akihiko Ishiyama, Masayuki Sasaki, Shin’ichi Takeda
Annals of Clinical and Translational Neurology

Abstract

We confirmed the safety and tolerability of TAS-205 in this study. TAS-205 decreased the total urinary excretion of PGD<sub>2</sub> metabolites in a dose-dependent manner, suggesting that TAS-205 might be a therapeutic option to treat DMD patients.

References

YearCitations

Page 1